Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction

Division of Cardiology, Kumamoto University School of Medicine, Japan.

OBJECTIVES. The present study was designed to compare the secretion patterns of two cardiac hormones--A-type (atrial) and B-type (brain) natriuretic peptides--from the ventricles in patients with old myocardial infarction. BACKGROUND. Plasma levels of these two natriuretic peptides are increased, and their secretion from the ventricles is augmented, in patients with congestive heart failure. METHODS. We measured the plasma levels of these two types of natriuretic peptides at the aortic root and the anterior interventricular vein in 42 patients with old myocardial infarction (anterior in 22 and inferior in 20) and 18 control subjects. RESULTS. The difference between the plasma levels of both A- and B-type natriuretic peptide in the anterior interventricular vein and aortic root was significantly greater in the groups with anterior and inferior infarction than in the control group (A-type [mean +/- SD] 380 +/- 290 and 247 +/- 205 pg/ml in the infarction groups vs. 11 +/- 14 pg/ml; B-type 497 +/- 445 and 75 +/- 73 pg/ml vs. 23 +/- 16 pg/ml, respectively). The difference between the plasma levels of each peptide at the anterior interventricular vein and aortic root had a significant negative linear correlation with left ventricular ejection fraction in both groups with infarction. The slope of the regression line of the arteriovenous difference of B-type natriuretic peptide at the anterior interventricular vein was significantly steeper in the anterior than in the inferior infarction group (left ventricular ejection fraction -12.801 vs. -1.891, p < 0.01). CONCLUSIONS. These results indicate that 1) the secretion of A- and B-type natriuretic peptide from the left ventricular increases in proportion to the severity of left ventricular dysfunction, and 2) secretion of B-type natriuretic peptide is much greater from the infarct than from the noninfarct region, suggesting that the regional ventricular wall stretch caused by infarction strongly stimulates secretion of B-type natriuretic peptide.

This article has been cited by other articles:

				K. Y. Jeong, K. Kim, T. Y. Kim, C. C. Lee, S. O. Jo, J. E. Rhee, Y. H. Jo, G. J. Suh, and A. J. Singer Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia Emerg. Med. J., February 1, 2011; 28(2): 122 - 127. [Abstract] [Full Text] [PDF]

				C. D. Steadman, S. Ray, L. L. Ng, and G. P. McCann Natriuretic Peptides in Common Valvular Heart Disease J. Am. Coll. Cardiol., May 11, 2010; 55(19): 2034 - 2048. [Abstract] [Full Text] [PDF]

				R. Talens-Visconti, M. Rivera Otero, M. J. Sancho-Tello, F. G. de Burgos, L. Martinez-Dolz, B. Sevilla, V. Climent, R. Cortes, A. Salvador, F. Sogorb, et al. Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure Eur Heart J Cardiovasc Imaging, January 1, 2006; 7(1): 45 - 52. [Abstract] [Full Text] [PDF]

				A Hirayama, H Kusuoka, H Yamamoto, Y Sakata, M Asakura, Y Higuchi, H Mizuno, K Kashiwase, Y Ueda, Y Okuyama, et al. Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction Heart, December 1, 2005; 91(12): 1573 - 1577. [Abstract] [Full Text] [PDF]

				R. Jarai, N. Iordanova, R. Jarai, A. Raffetseder, W. Woloszczuk, M. Gyongyosi, G. Geyer, J. Wojta, and K. Huber Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide Eur. Heart J., February 1, 2005; 26(3): 250 - 256. [Abstract] [Full Text] [PDF]

				J.-R. Blom, A. W.J. van 't Hof, J. P.S. Henriques, J. H. Geertman, R. Slingerland, and J. C.A. Hoorntje NT-proBNP: a marker for successful myocardial reperfusion in AMI patients treated with primary percutaneous coronary intervention Eur J Heart Fail, October 1, 2004; 6(6): 749 - 752. [Full Text] [PDF]

				S. Suzuki, M. Yoshimura, M. Nakayama, Y. Mizuno, E. Harada, T. Ito, S. Nakamura, K. Abe, M. Yamamuro, T. Sakamoto, et al. Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction: A Long-Term Follow-Up Analysis Circulation, September 14, 2004; 110(11): 1387 - 1391. [Abstract] [Full Text] [PDF]

				C. Hall Essential biochemistry and physiology of (NT-pro)BNP Eur J Heart Fail, March 15, 2004; 6(3): 257 - 260. [Abstract] [Full Text] [PDF]

				M. Vanderheyden, J. Bartunek, and M. Goethals Brain and other natriuretic peptides: molecular aspects Eur J Heart Fail, March 15, 2004; 6(3): 261 - 268. [Abstract] [Full Text] [PDF]

				P.-Y. Marie, P. M. Mertes, N. Hassan-Sebbag, N. de Talence, K. Djaballah, W. Djaballah, J. Friberg, P. Olivier, G. Karcher, F. Zannad, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers J. Am. Coll. Cardiol., February 4, 2004; 43(3): 353 - 359. [Abstract] [Full Text] [PDF]

				D. Mariano-Goulart, M.-C. Eberle, V. Boudousq, A. Hejazi-Moughari, C. Piot, C. C. de Kerleau, R. Verdier, M.-L. Barge, F. Comte, N. Bressot, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure Eur J Heart Fail, August 1, 2003; 5(4): 481 - 488. [Abstract] [Full Text] [PDF]

				H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]

				C.A. Kelly, D.E. Newby, T.A. Mcdonagh, T.W. Mackay, J. Barr, N.A. Boon, H.J. Dargie, and N.J. Douglas Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema. Effects on plasma brain natriuretic peptide concentrations Eur. Heart J., September 1, 2002; 23(17): 1379 - 1386. [Abstract] [Full Text] [PDF]

				P. Jourdain, M. Bellorini, F. Funck, Y. Fulla, N. Guillard, J. Loiret, B. Thebault, N. Sadeg, and M. Desnos Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study Eur J Heart Fail, June 1, 2002; 4(3): 263 - 267. [Abstract] [Full Text] [PDF]

				N. Yamamoto, H. Yasue, Y. Mizuno, M. Yoshimura, H. Fujii, M. Nakayama, E. Harada, S. Nakamura, T. Ito, and H. Ogawa Aldosterone Is Produced From Ventricles in Patients With Essential Hypertension Hypertension, May 1, 2002; 39(5): 958 - 962. [Abstract] [Full Text] [PDF]

				T. P. Weber, C. Raufhake, M. A. Gro{beta}e Hartlage, N. Rolf, J. Stypmann, H. Van Aken, E. Berendes, and A. Mei{beta}ner Naloxone prevents increased atrial natriuretic peptide release during regional myocardial ischaemia and stunning in awake dogs Br. J. Anaesth., January 1, 2002; 88(1): 87 - 93. [Abstract] [Full Text] [PDF]

				A. Luchner, C. Hengstenberg, H. Lowel, J. Trawinski, M. Baumann, G. A.J. Riegger, H. Schunkert, and S. Holmer N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction: A Marker Of Cardio-Renal Function Hypertension, January 1, 2002; 39(1): 99 - 104. [Abstract] [Full Text] [PDF]

				J G Crilley and M Farrer Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction Heart, December 1, 2001; 86(6): 638 - 642. [Abstract] [Full Text] [PDF]

				I. Morishima, T. Sone, K. Okumura, H. Tsuboi, J. Kondo, H. Mukawa, H. Matsui, Y. Toki, T. Ito, and T. Hayakawa Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1202 - 1209. [Abstract] [Full Text] [PDF]

				K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Hisanaga, T. Kamijo, and M. Kinoshita Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction J Appl Physiol, August 1, 2000; 89(2): 458 - 464. [Abstract] [Full Text] [PDF]

				S. Yasuda, Y. Goto, T. Baba, T. Satoh, H. Sumida, S. Miyazaki, and H. Nonogi Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function J. Am. Coll. Cardiol., July 1, 2000; 36(1): 115 - 121. [Abstract] [Full Text] [PDF]

				M. T. Rademaker, V. A. Cameron, C. J. Charles, E. A. Espiner, M. G. Nicholls, C. J. Pemberton, and A. M. Richards Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H731 - H740. [Abstract] [Full Text] [PDF]

				S. Yasuda, Y. Goto, H. Sumida, T. Noguchi, T. Baba, S. Miyazaki, and H. Nonogi Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure Hypertension, June 1, 1999; 33(6): 1374 - 1378. [Abstract] [Full Text] [PDF]

				R. O. Bonow New Insights Into the Cardiac Natriuretic Peptides Circulation, June 1, 1996; 93(11): 1946 - 1950. [Full Text]

				T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text]